本文应用联合抗过敏新鲜血浆疗法及单纯常规液体疗法各治疗中晚期流行性出血热(EHF)患者12例。结果:经联合抗过敏新鲜血浆疗法治疗后,患者的尿蛋白消失快,BUN上升水平低,血小板迅速向正常恢复,越期率高,完成治疗后患者无一死亡。而单纯常规液体疗法治疗的对照组患者的主要并发症发生率为16.7％,治愈率仅达83.3％。上述结果证明,联合抗过敏新鲜血浆疗法是治疗中晚期EHF行之有效的措施。 In this paper, combined anti-allergic fresh plasma therapy and conventional liquid therapy in the treatment of mid and late epidemic hemorrhagic fever (EHF) in patients with 12 cases. Results: The combination of anti-allergic fresh plasma therapy, the patient’s urine protein disappeared quickly, the level of BUN increased low platelet recovery to normal, the high rate of overdue, the completion of treatment, no patient died. The simple complication of liquid therapy in the control group, the main complication rate was 16.7%, the cure rate was only 83.3%. The above results show that the combination of anti-allergic fresh plasma therapy is an effective measure for the treatment of advanced EHF.